Cardiovascular diseases (CVD), and in particular cerebrovascular and ischemic heart diseases, are leading causes of death globally.
SUMMARY
Cardiovascular diseases (CVD), and in particular cerebrovascular and ischemic heart diseases, are leading causes of death globally. 1 Lowering circulating lipids is an important treatment strategy to reduce risk. 2, 3 However, some pharmaceutical mechanisms of reducing CVD may increase risk of fatty liver disease or other metabolic disorders. 4, 5, 6 To identify potential novel therapeutic targets, which may reduce risk of CVD without increasing risk of metabolic disease, we focused on the simultaneous evaluation of quantitative traits related to liver function and CVD. Using a combination of low-coverage (5x) wholegenome sequencing and targeted genotyping, deep genotype imputation based on the TOPMed reference panel 7 , and genome-wide association study (GWAS) meta-analysis, we analyzed 12 liverrelated blood traits (including liver enzymes, blood lipids, and markers of iron metabolism) in up to 203,476 people from three population-based cohorts of different ancestries. We identified 88 likely causal protein-altering variants that were associated with one or more liver-related blood traits. We identified several loss-of-function (LoF) variants reducing low-density lipoprotein cholesterol (LDL-C) or risk of CVD without increased risk of liver disease or diabetes, including variants in known lipid genes (e.g. APOB, LPL). A novel LoF variant, ZNF529:p.K405X, was associated with decreased levels of LDL-C (P=1.3x10 -8 ) but demonstrated no association with liver enzymes or non-fasting blood glucose levels.
Silencing of ZNF529 in human hepatocytes resulted in upregulation of LDL receptor (LDLR) and increased LDL-C uptake in the cells, suggesting that inhibition of ZNF529 or its gene product could be used for treating hypercholesterolemia and hence reduce the risk of CVD. Taken together, we demonstrate that simultaneous consideration of multiple phenotypes and a focus on rare protein-altering variants may identify promising therapeutic targets.
MAIN TEXT
We combined several approaches for genomic discovery to identify independent variants associated with 12 liver-related phenotypes (see Supplementary Figure 1 for an overview). The 12 traits we examined were related to: i) blood lipid levels which impact cardiovascular, neurological and eye-related diseases: total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels; ii) C-reactive protein (CRP; only values <15 mmol/L were included) which is predictive of cardiovascular disease; 8 iii) enzymes which mainly reflect liver function:
alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and gamma-glutamyltransferase (GGT); and iv) iron-related phenotypes: serum iron, total iron binding capacity (TIBC), and transferrin saturation percentage (TSP).
Using four primary discovery designs, we identified 763 unique variants within 340 genomic regions (i.e. loci) associated with at least one of the 12 quantitative liver-related blood traits. We identified genome-wide significant associations with at least one trait at 88 presumed causal proteinaltering variants, of which 9 result in LoF of a specific protein -3 frameshift indels and 6 premature stop
codons.
First, we tested for association with liver-related traits among 69,479 participants (Supplementary Table 1 ) in the population-based Nord-Trøndelag Health Study (HUNT) in Norway. 9 26 million polymorphic genetic variants were imputed with sufficient quality and at least 10 alleles using the TOPMed multi-ethnic reference panel consisting of 60,039 deeply sequenced genomes. 7 We used a linear mixed model 10 to account for relatedness in the HUNT sample set and identified 246 genomewide statistically significant (P<5x10 Fourth, we performed a trans-ancestry meta-analysis by combining summary statistics based on the primary discovery effort in HUNT with additional GWAS statistics from Sardinia (SardiNIA cohort) 15 and Japan (Biobank Japan) 16 , resulting in an analysis of up to 203,476 participants and 31.5 million unique variants (Supplementary Figure 3) . This analysis identified 388 significant variants, identifying 93 additional loci (Supplementary Table 5 ) and an additional of 16 protein-altering locus index variants, including the previously described Sardinian-specific LoF variant HBB:p.Q40X, which has been associated with beta thalassemia 17 and decreased LDL-C and TC ( Table 1) . 18 After combining results across all samples and discovery strategies, we were particularly interested in nine variants which appeared to result in LoF of a gene, including the novel association between ZNF529:p.K405X and decreased LDL-C ( Table 1) . We observed 4 additional LoF variants also resulting in substantially decreased LDL-C (3 nonsense variants in APOB, and a common frameshift indel in SLC22A1; Table 1 ). The remaining LoF were associations with other blood lipid traits (HBB:p.Q40X
with TC in addition to LDL-C, LPL:p.S474X with TG, and LIPC:p.G247Afs*11 with HDL-C). Of the 9 LoF variants, the five within APOB, LPL, LIPC, and ZNF529 were not even nominally significantly associated (P>0.05) with liver enzymes ALT, AST, ALP or GGT (Figure 2b ). This suggests that these genetic variants do not cause liver damage, suggesting these genes may serve as potential drug targets to reduce LDL-C. We expect that protein-altering variants which are the peaks of association represent functional variants that pinpoint biologicallyrelevant genes and potential drug targets. We also sought novel genes that decreased cardiovascular risk factors (such as LDL-C), but did not increase risk of liver disease or impact liver enzymes. Thus, we focused on the novel association between ZNF529:p.K405X and LDL-C (P=1.3x10 (Figure 1) . Using labeled LDL-C, we observed that ZNF529-silencing resulted in a marked increase in LDL-C uptake by HepG2 cells and 2.2-fold increase in intracellular cholesterol content (P=0.007). These findings suggest that ZNF529 is a novel regulator of plasma LDL-C via regulation of hepatic LDLR.
Figure 1. ZNF529 silencing induces LDLR expression and LDL-C uptake. (a) Efficient silencing of ZNF529 in HepG2 cells via siRNA as shown by qPCR using GAPDH as reference (N=15). (b) ZNF529 silencing in HepG2 cells induces LDLR mRNA as shown by qPCR using GAPDH as reference (N=15), (c, d) and LDLR protein as shown by Western blot using β-actin as loading control (N=4). (e) ZNF529 silencing in HepG2 cells increases LDL-C uptake as evidenced by enhanced fluorescence of Dil-LDL. scale bars=200 µm, (N=6), (f) and leads to increased intracellular cholesterol (N=12). Values are presented as mean ± SD showing all points.
Individuals heterozygous for ZNF529:p.K405X (N=109) had a mean LDL-C level of 2.58 mmol/L vs. 3.44 mmol/L in non-carriers. This reduction in LDL-C of 25% in heterozygous carriers is in the range of what is seen for 5 years of treatment with 40mg of statin (-35% change). 25 We only observed one homozygous female carrier. Despite being obese and server hypertensive, she was alive at age >90 years and had no diagnosis of cardiovascular disease, liver disease, or diabetes, and had an LDL-C level slightly below average for her age group (3.45 mmol/L vs. mean 3.8 mmol/L for women >90 years old). This one individual with a natural absence of both copies of ZNF529 suggests that homozygous knockout of this gene is compatible with survival.
We also highlight 17 protein-altering variants with an impact >1 standard deviation on the trait (Figure 2a, Supplementary Figure 4 , and Supplementary Table 6 ). For lipids, protein-altering variants in APOB, LDLR, and PCSK9 that impact LDL-C, and in CETP that impact HDL-C, are well known. 19 However, for liver enzyme traits, TNK1:p.G574V is a new finding to complement genes previously known to impact liver enzymes including ALPL (with ALP),
26
GPLD1 (with ALP), and GPT (with ALT). 27 This rare TNK1 variant, present in 46 individuals (1 in 814 individuals), was identified in Norwegian sequenced samples, genotyped using the custom array, and observed to have a large impact on ALP (beta=1.2, P=1.7x10 
) associated with a lipid trait (HDL-C, LDL-C, TG, TC), the maximum effect size in terms of the allele associated with good lipid health (e.g. lowered LDL-C, increased HDL-C, lowered TG, and lowered TC) is compared to the minimum pvalue for association with liver trait (ALT, ALP, AST, GGT). Nominal P-value of 0.05 (vertical dashed line) is indicated to highlight variants in the bottom right quadrant which lack significance for association with liver traits. These variants are better drug target candidates given estimated favorable lipid-effects on health and absence of association with potentially unfavorable liver traits.
To further characterize genes that may be involved in these liver-related phenotypes, we performed gene-based burden tests, using SKAT-O as implemented in SAIGE-GENE, 28 for all proteinaltering variants with frequency below 0.5% in the HUNT dataset. Although twenty-eight unique genes were significantly associated (P<2x10 -7 ) with at least one of 12 liver traits (Supplementary Table 7 we found a phenome-wide significant (P<3.5x10 To identify potentially useful drug targets that may reduce blood lipid levels and risk of coronary artery disease (CAD) and type 2 diabetes (T2D) without an increased risk of fatty liver disease, we attempted to identify variants that decreased LDL-C and/or TG, but were not associated with changes in liver enzyme levels (P>0.05, From the PheWAS, we observed other interesting associations. For example, we identify alleles that reduce risk of myocardial infarction (MI) but increase risk liver and pulmonary disease for SERPINA1:p.E366K, which is known for causing alpha-1-antitrypsin deficiency 31 . This pattern suggests caution in ongoing efforts to treat acute MI with exogenous administration of alpha-1-antitrypsin. 32, 33 Another interesting and novel finding from UK Biobank PheWAS is the association between TMPRSS6:p.V727A and an increased risk of 'nonspecific chest pain'. We initially found this allele to be associated with decreased iron and TSP in HUNT, -perhaps suggesting that the association with chest pain might be explained by anemia-induced cardiac ischemia (Figure 3, Supplementary Figure 5 and Supplementary Tables 7, 9 ). Further studies are obviously warranted to uncover the biological mechanisms underlying these associations, however, each of them could help inform clinical implications of targeting the underlying gene or gene product.
In summary, by using four complementary approaches for genomic discovery: sequencing, imputation, array-based genotyping and trans-ancestry meta-analysis, we identified >300 loci associated with liver-related quantitative traits, including 88 presumed causal protein-altering variants. By considering disease end-point associations with disease phenotypes for protein-altering variants, we prioritize several novel genes as potential drug targets. The newly uncovered association and in vitro studies indicate that ZNF529 LoF is associated with lower plasma LDL-C which could be explained by induction of LDLR in hepatic cells and increased LDL-C uptake. While these findings indicate a therapeutic potential for lowering plasma LDL-C by ZNF529 inhibition, further studies are warranted to elucidate the mechanisms by which ZNF529 regulates LDLR and LDL-C uptake in the liver. We further confirmed several genes as promising drug targets for cardiometabolic disease with no expected impact on liver disease by testing association with impactful protein-altering variants in APOB and LPL, to reduce LDL-C and risk of coronary artery disease, and COBLL1, to reduce TG and risk of type 2 diabetes. Future functional studies to rule out their role in liver and other cardiometabolic disease will likely contribute to better prediction of outcomes and disease progression and facilitate development of personalized treatments.
All together, we demonstrate that identifying rare protein-altering variants and careful consideration of multiple phenotypes in well-powered studies may point to promising drug targets. We used a variety of approaches to identify rare protein-altering variants, and we found that if exome sequencing is prohibitively expensive, sequencing a subset of samples followed up with a custom genotyping array can be a viable strategy to identify impactful rare variants. 
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